In support of this premise, recent studies have demonstrated that the TLR2/MyD88/miRNA155/Ets-1 pathway is required for the production of autoantibodies that form DNA-containing immune complexes [112] and that increased TLR2 expression promotes IL-17 production in SLE patients [117]. This evidence concerns the gene IL17A and systemic lupus erythematosus.